ArticleBMC nutrition2025
Effects of resveratrol supplementation on serum concentrations of plasminogen activator inhibitor-1, fibroblast growth factor 21, and adiponectin in patients with nonalcoholic fatty liver disease.
Article in BMC nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effect of resveratrol supplementation on anthropometric indices, adiponectin and leptin levels in individuals with overweight and obesity: a graded, systematic review and meta-analysis of randomized controlled trials.International journal of obesity (2005) · 2026Pooled it
- Comparative Efficacy of Herbal Products for Improving Liver Enzymes and Inflammation in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Network Meta-Analysis.Gastro hep advances · 2026Review
- Comparative Efficacy of Herbal Products on Metabolic Parameters in Metabolic-Dysfunction Associated Liver Disease: A Systematic Review and Network Meta-Analysis.Gastro hep advances · 2026Review
- Therapeutic Potential of Resveratrol in Cancer and Neurodegenerative Disorders: A Current Review.BioFactors (Oxford, England)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder which may progress from simple steatosis to liver failure. Patients with NAFLD have higher levels of systemic inflammation. Resveratrol, a natural polyphenolic compound, has been shown to have anti-inflammatory effects through various mechanisms. The aim of this study was to evaluate the effect of resveratrol supplementation on serum levels of plasminogen activator inhibitor-1 (PAI-1), adiponectin, fibroblast growth factor-21 (FGF-21) as well as high-sensitivity C-reactive protein (hs-CRP) in patients with NAFLD.
methodsIn this double-blind randomized controlled trial, 50 adults with NAFLD aged 20-60 years were allocated into two groups; the intervention and the placebo group received two capsules per day each containing 300 mg resveratrol and placebo, respectively. Fasting blood samples and anthropometric measurements were collected for all patients at baseline and at the end of the trial. Cges in the outcomes were analyzed using analysis of covariance (ANCOVA).
resultsAfter 12 weeks of intervention, resveratrol supplementation did not cause significant changes in serum levels of liver enzymes including alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), and alkaline phosphatase (ALP) compared to the control group. No significant differences were observed in the serum levels of PAI-1, adiponectin, FGF-21, and hs-CRP between the two groups at the end of the study.
conclusionsResveratrol supplementation for 12 weeks did not show favorable effects on serum levels of liver enzymes, PAI-1, adiponectin, FGF-21, and hs-CRP.
trial registrationIranian Registry of Clinical Trials (IRCT201511233664N16) (2016-02-08).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.